

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Dermatology</b>				
Wounds	Growth hormone-releasing hormone (GHRH); GHRH receptor (GHRHR)	<p>Mouse studies suggest that GHRHR agonists could help treat skin wounds. In a mouse model of skin wounds, topical GHRH or a GHRHR agonist increased fibroblast density and the rate of healing compared with those of untreated control wounds on the same animal. Ongoing work includes testing other GHRH analogs in animal models of skin wounds.</p> <p>Theratechnologies Inc.'s GHRH analog Tesamorelin (TH9507) is in registration to treat lipodystrophy in HIV-infected patients and in Phase II testing to treat abdominal obesity and cognitive dysfunction.</p> <p>Akela Pharma Inc.'s peptide analog of GHRH is in Phase II testing to treat cachexia in patients with chronic renal failure.</p> <p><b>SciBX 3(41); doi:10.1038/scibx.2010.1232</b>  <b>Published online Oct. 21, 2010</b></p>	Patented by the University of Miami; available for licensing	<p>Dioufa, N. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Oct. 11, 2010; doi:10.1073/pnas.1013942107</p> <p><b>Contact:</b> Andrew V. Schally, Veterans Affairs Medical Center and South Florida VA Foundation for Research &amp; Education, Miami, Fla.  e-mail: <a href="mailto:Andrew.schally@va.gov">Andrew.schally@va.gov</a></p> <p><b>Contact:</b> Hippokratris Kiaris, National and Kapodistrian University of Athens Medical School, Athens, Greece  e-mail: <a href="mailto:hkiaris@med.uoa.gr">hkiaris@med.uoa.gr</a></p>